{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["177Lu-DOTA-TLX591"]],"indication":"PSMA-expressing metastatic castration-resistant prostate cancer","name":"ProstACTSelect","nct_id":"NCT04786847","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=prostactselect-nct04786847. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ProstACTSelect","arms":[{"description":"Two single IV infusions of 76 mCi (2.8 GBq) each (equivalent to a 45 mCi/m2 administered activity in a standard 1.7m2 individual) of 177Lu-DOTA-TLX591, given 14 days apart. This therapy will be administered with the current standard of care treatment regimens.","label":"Single administration of 177Lu-DOTA-TLX591","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2023-09-30","type":"ACTUAL"},"conditions":["Metastatic Prostate Cancer"],"enrollment":{"count":30,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"177Lu-DOTA-TLX591","otherNames":[],"type":"BIOLOGICAL"}],"last_update":"2024-02-12","lead_sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","official_title":"A Phase 1 Safety, Tolerability, Biodistribution, Dosimetry and Efficacy Study of 177Lu-DOTA-TLX591 With Best Standard of Care in Patients With PSMA Expressing Metastatic Castration-resistant Prostate Cancer","overall_status":"COMPLETED","phases":["PHASE1"],"primary_completion_date":{"date":"2023-09-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0","timeFrame":"Day 1 to 5 years"}],"references":[],"start_date":{"date":"2022-01-30","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"177Lu-DOTA-TLX591 Safety, Biodistribution and Dosimetry Study","url":"https://clinicaltrials.gov/study/NCT04786847"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/prostactselect-nct04786847"}